The development of chronic kidney disease (CKD) is associated with poor outcomes largely due an increased likelihood of adverse cardiovascular events. Many factors are playing a role in cardiovascular disease in CKD including the development of vascular calcification (VC). Studies have indeed shown that the presence of VC is associated with decreased survival among patients with CKD. The pathogenesis of VC is itself multi-factorial. LikeLy playing a significant role is the altered mineral metabolism of CKD. Management of the altered mineral metabolism in CKD is quite difficult and may also play a role in the pathogenesis of VC. In this manuscript, we will review the pathogenesis of the altered mineral metabolism of CKD, its management, and how both may play a role in the development of VC.
Avram, M.M. et al. (1996) Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia . Am J Kidney Dis28(6): 924—930 .
2.
Blacher, J. et al. (2003) Aortic pulse wave velocity index and mortality in end-stage renal disease . Kidney Int63(5): 1852—1860 .
3.
Block, G.A. et al. (2005) Kidney Int68(4): 1815—1824 .
4.
Block, G.A. et al. (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients . Kidney Int71(5): 438—441 .
5.
Centers for Disease Control and Prevention (CDC). (2007) Prevalence of chronic kidney disease and associated risk factors—United States, 1999—2004 . MMWR Morb MortalWkly Rep56(8): 161—165 .
6.
Chen, N.X. et al. (2002) Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells . Kidney Int62: 1724—1731 .
7.
Chertow, G.M. et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients . Kidney Int62: 245—252 .
8.
Cunningham, J. et al. (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism . Kidney Int68(4): 1793—1800 .
9.
Davies, M.R. and Hruska, K.A. (2001) Pathophysiological mechanisms of vascular calcification in end-stage renal disease . Kidney Int60: 472—479 .
10.
Go, A.S. et al. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization . N Engl J Med351(13): 1296—1305 .
11.
Goodman, W.G. et al. (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy . Kidney Int46: 1160—1166 .
12.
Guh, J.Y. et al. (2002) Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients . Am J Kidney Dis39(6): 1245—1254 .
13.
Gutierrez, O. et al. (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease . J Am Soc Nephrol16: 2205—2215 .
14.
Hruska, K.A. and Teitelbaum, S.L. (1995) Renal osteodystrophy . N Engl J Med333: 166—174 .
15.
Hruska, K.A. et al. (2004) Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy . Semin Nephrol24(1): 25—38 .
16.
Jung, H.H. et al. (2006) Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis . Nephrol Dial Transplant21(7): 1915—1920 .
17.
Kestenbaum, B. et al. (2004) Survival following parathyroidectomy among United States dialysis patients . Kidney Int66(5): 2010—2016 .
18.
Kurz, P. et al. (1994) Evidence for abnormal calcium homeostasis in patients with adynamic bone disease . Kidney Int46(3): 855—861 .
19.
Lafage-Proust, M.H. et al. (1999) Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction . J Clin Endocrinol Metab84: 512—519 .
20.
London, G.M. et al. (2007) Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency . J Am Soc Nephrol18(2): 613—620 .
21.
Mai, M.L. et al. (1989) Calcium acetate, an effective phosphorus binder in patients with renal failure . Kidney Int36(4): 690—695 .
22.
Malluche, H.H. et al. (2004) The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?Nephrol Dial Transplant19(Suppl 1): i9—13 .
23.
Okuno, S. et al. (2007) Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients . Am J Kidney Dis49(3): 417—425 .
24.
Picton, M.L. et al. (2000) Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure . Kidney Int58: 1440—1449 .
25.
Qunibi, W.Y. et al. (2004) Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate renagel evaluation (CARE study) . Kidney Int65: 1914—1926 .
26.
Rahman, M. et al. (2006) Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate . Ann Intern Med144(3): 172—180 .
27.
Sarnak, M.J. et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention . Circulation108(17): 2154—2169 .
28.
Satomura, K. et al. (1988) Renal 25-hydroxyvitamin D3-1-hydroxylase in patients with renal disease . Kidney Int34(5): 712—716 .
29.
Shimada, T. et al. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism . J Clin Invest113: 561—568 .
30.
Slatopolsky, E. et al. (1968) Control of phosphate excretion in uremic man . J Clin Invest47: 1865—1874 .
31.
Slatopolsky, E. et al. (1996) Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro . J Clin Invest97: 2534—2540 .
32.
Slatopolsky, E. et al. (2000) A novel mechanism for skeletal resistance in uremia . Kidney Int58: 753—761 .
33.
Suki, W.N. et al. (2007). Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients . Kidney Int72: 1130—1137 .
34.
Tanaka,Y. and Deluca, H.F. (1973) The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus . Arch Biochem Biophys154: 566—574 .
35.
Teng, M. et al. (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy . N Engl J Med349(5): 446—456 .
36.
Teng, M. et al. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study . J Am Soc Nephrol16(4): 1115—1125 .
37.
Tentori, F. et al. (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs . Kidney Int70(10): 1858—1865 .
38.
Tonelli, M. et al. (2005) Cholesterol and Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease . Circulation112(17): 2627—2633 .
39.
Tyson, K.L. et al. (2003) Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification . Arterioscler Thromb Vasc Biol23: 489—494 .
40.
Yang, H. et al. (2004) Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro . Kidney Int66: 2293—2299 .
41.
Young, E.W. et al. (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study . Kidney Int67(3): 1179—1187 .
